Join us for an informal in-person only event to discuss the oral presentation from earlier in the day at ADA regarding Sernova’s updated interim data from the first cohort of the Phase 1/2 study involving pancreatic islet allotransplantation into pre-vascularized Cell Pouch™ in patients with type 1 diabetes and discussion of our iPSC derived islet-like clusters planned to enter the clinic in 2024 through our collaboration with Evotec SE.

Senior management will be available to answer questions from analysts and investors.